<DOC>
	<DOCNO>NCT02721875</DOCNO>
	<brief_summary>The objective trial evaluate safety , tolerability , maximum tolerate dose ( MTD ) , pharmacokinetics preliminary efficacy volasertib two dose schedule intravenous volasertib monotherapy combination azacitidine patient myelodysplastic syndrome ( MDS ) hypomethylating agent ( HMA ) treatment failure .</brief_summary>
	<brief_title>Trial Volasertib With Without Azacitidine Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : Patients 18 year old diagnosis WHO classificationdefined primary treatmentrelated myeloid neoplasm classify follow : Refractory anaemia excess blast ( RAEB ) 1 ( 5 % 9 % marrow blast ) RAEB2 ( 10 % 19 % marrow blast 5 % 19 % peripheral blast ) Chronic Myelomonocytic Leukaemia ( CMML ) ( 5 % 19 % blast ) white blood cell ( WBC ) count &lt; 13000/mm3 Acute Myeloid Leukaemia ( AML ) ( 20 % 29 % marrow blast , i.e. , RAEBt accord FrenchAmericanBritish [ FAB ] classification ) WBC count &lt; 10000/mm3 Patients classified intermediate , high highrisk accord Revised International Prognostic Scoring System ( IPSSR ) time enrolment Patients receive maximum 24 cycle frontline HMA treatment prior enrolment . Patients must receive minimum prior dosing schedule either : Azacitidine 75 mg/m2 x 5 day per cycle 50 mg/m2 x 7 day per cycle , Decitabine 20 mg/m2 x 5 day per cycle , SGI110 60 mg/m2 x 5 day per cycle Patients must meet either one follow criterion : Progressive disease ( PD , accord 2006 International Working Group ( IWG ) criterion ) time initiation prior HMA treatment , Relapse initial complete ( CR ) partial remission ( PR ) haematological improvement ( HI ) ( accord 2006 IWG criterion ) ; Failure achieve complete partial remission HI ( accord 2006 IWG ) evidence progression ( i.e. , Stable Disease [ SD ] ) least six cycle prior azacitidine treatment least four cycle prior HMA treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 screening Signed write informed consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) local legislation Exclusion criterion : Prior systemic therapy ( include investigational drug ) MDS , CMML AML within 14 day treatment study medication . Patients require intervention white blood cell count control hydroxyurea , chemotherapy , leukapheresis . Prior exposure one line HMA base treatment . Prior exposure volasertib polokinase inhibitor Patients unable tolerate prior HMA treatment Patients history hematopoietic stem cell transplant ( HSCT ) Known hypersensitivity trial drug excipients Second malignancy currently require active therapy ( except hormonal/antihormonal treatment , e.g. , prostate breast cancer ) . QTcF value &gt; 470 m QT prolongation deem clinically relevant investigator ( e.g. , congenital long QT syndrome ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>